Top Spasticity Treatment Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Spasticity Treatment Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Spasticity Treatment industry players.

Spasticity Treatment Market Competitive Landscape

The global spasticity treatment market is highly competitive, with prominent players focusing sharp attention on improving product portfolios and patient outcomes. Companies are investing in and developing new therapies, mainly in the form of oral medications or botulinum toxin-based treatments. Most major firms on the market go for strategic partnerships, acquisitions, and regional expansions in their efforts to position themselves in the industry.

  • NeuroRestore (US, 2018): New neurostimulation approaches will be developed by NeuroRestore aimed at managing patients with spasticity and other movement disorders. Currently, the company develops an invasive neurostimulation device for curing spasticity, where it is a manifestation of neurological diseases such as cerebral palsy and stroke, and improving mobility in patients with this condition. It can also be incorporated in existing treatment regimens, thus creating a more individual treatment regimen.
  • Neurosteer (Israel, 2015): Neurosteer plans to develop wearable devices for administering neurostimulation without moving the patient's body for personalized treatments against neurological disorders such as spasticity. The device can deliver real-time brain imaging, thus, enabling it to distinguish normal from abnormal activities in the brain and analyze the impact of treatment.

Top Player’s Company Profile

  • Allergan
  • Ipsen
  • Merz Pharmaceuticals
  • Zambon
  • Teva Pharmaceutical Industries
  • AbbVie
  • Mylan N.V.
  • UCB Pharma
  • Medtronic
  • Novartis
  • Mallinckrodt Pharmaceuticals
  • Bausch Health
  • Lundbeck
  • Amgen
  • Sanofi

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Spasticity Treatment Market size was valued at USD 1.57 Billion in 2024 and is poised to grow from USD 1.65 Billion in 2025 to USD 2.42 Billion by 2033, growing at a CAGR of 4.9% during the forecast period (2026–2033).

The global spasticity treatment market is highly competitive, with prominent players focusing sharp attention on improving product portfolios and patient outcomes. Companies are investing in and developing new therapies, mainly in the form of oral medications or botulinum toxin-based treatments. Most major firms on the market go for strategic partnerships, acquisitions, and regional expansions in their efforts to position themselves in the industry. 'F. Hoffmann-La Roche Ltd ', 'GlaxoSmithKline plc ', 'Medtronic ', 'Pfizer Inc ', 'Ipsen Pharma ', 'UCB Pharma Ltd ', 'INMED PHARMACEUTICALS INC ', 'Orient Pharma ', 'Taj Pharmaceuticals Limited ', 'Johnson & Johnson Services, Inc. ', 'MediciNova, Inc. ', 'Sun Pharmaceutical Industries Ltd ', 'Novartis AG ', 'Teva Pharmaceutical Industries Ltd ', 'Merz Pharma ', 'Acorda Therapeutics, Inc.'

Among the most significant drivers of growth in the spasticity treatment market is the growing prevalence of neurological diseases such as cerebral palsy, multiple sclerosis, and stroke-induced spasticity. Against the backdrop of the growing incidence of these disorders across the globe, there is a growing demand for effective treatments like oral drugs, physical therapy, and botulinum toxins, which is fueling the growth of the market.

Implementation of Minimally Invasive Procedures: In the management of spasticity, there has been an increased trend towards the use of less invasive treatment methods, including intrathecal medication infusion devices and botulinum toxin injections. Particularly with the localized type of spasticity, such treatment is extremely common among doctors as it provides temporary relief but with less pain and a shorter duration of recovery. This is particularly common in this situation.

North America is the dominant player in the spasticity treatment market, driven by advanced healthcare infrastructure and increasing research and development activities. The region has the backing of well-established reimbursement policies and the dominant market presence of major players. The United States has a strong hold in the regional market, followed by Canada and Mexico. Each country contributes uniquely to the growth of the market through different healthcare measures and treatment accessibility programs. The regional market is characterized by high adoption rates for new treatments and increasing awareness of drug options available for spasticity.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Lymphedema Treatment Market
Buy Now GET FREE SAMPLE
Neuroendocrine Tumors Treatment Market
Buy Now GET FREE SAMPLE
Morquio Syndrome Treatment Market
Buy Now GET FREE SAMPLE
Hyperhidrosis Treatment Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Spasticity Treatment Market
Spasticity Treatment Market

Report ID: SQMIG35D2301

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE